TORONTO, October 25, 2018
Today at the annual Clinical Trials on Alzheimer's Disease (CTAD) conference, Cortexyme is reporting results from their Phase 1B trial for Alzheimer’s disease using COR388; a bacterial protease inhibitor. Though the primary focus of the study was safety and pharmacokinetics, exploratory analysis of cognition showed that Winterlight’s cognitive assessment detected significant improvement for treatment relative to placebo. Significant improvement was not observed on the MMSE or CANTAB measures of cognition. Sample sizes were small (treatment = 6, placebo = 3) and these analyses were exploratory, but they show great promise for the use of Winterlight’s technology in clinical trials.
You can read Cortexyme’s full press release here:
Winterlight Labs is commercializing a proprietary language-based diagnostic system that analyzes natural speech to detect and monitor dementia, Alzheimer’s, aphasia, and various other cognitive conditions. Winterlight's scalable platform uses short recorded speech samples to analyze hundreds of linguistic cues, and can detect dementia and other conditions with a high level of accuracy-. This is a major improvement over current pencil-and-paper tests which are time-consuming, costly, and difficult to administer. The platform has applications in drug trials, long-term and primary care, and speech-language pathology.
Since its founding, Winterlight Labs has seen strong interest from pharmaceutical companies and other potential partners who view the technology as a major improvement over current methods of detection or screening. The company has gained support from the pan-Canadian AGE-WELL Network of Centres of Excellence (NCE), the Ontario Brain Institute, Ontario Centres of Excellence, and the University of Toronto Banting and Best Centre for Innovation and Entrepreneurship. For more information, visit www.winterlightlabs.com.
Liam Kaufman, CEO
liam [at] winterlightlabs.com